An individualised versus a conventional pneumoperitoneum pressure strategy during colorectal laparoscopic surgery: rationale and study protocol for a multicentre randomised clinical study

O. Diaz-Cambronero, G. Mazzinari, C. L. Errando, M. J. Schultz, B. Flor Lorente, N. García-Gregorio, M. Vila Montañés, Daniel Robles-Hernández, L. E. Olmedilla Arnal, A. Martín-De-Pablos, A. Marqués Mari, M. P. Argente Navarro and for the IPPCollapse-II study group

Abstract

Background: A recent study shows that a multifaceted strategy using an individualised intra-abdominal pressure titration strategy during colorectal laparoscopic surgery results in an acceptable workspace at low intra-abdominal pressure in most patients. The multifaceted strategy, focused on lower to individualised intra-abdominal pressures, includes prestretching the abdominal wall during initial insufflation, deep neuromuscular blockade, low tidal volume ventilation settings and a modified lithotomy position. The study presented here tests the hypothesis that this strategy improves outcomes of patients scheduled for colorectal laparoscopic surgery.

Methods: The Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery versus Standard Therapy (IPPCollapse-II) study is a multicentre, two-arm, parallel-group, single-blinded randomised 1:1 clinical study that runs in four academic hospitals in Spain. Patients scheduled for colorectal laparoscopic surgery with American Society of Anesthesiologists classification I to III who are aged > 18 years and are without cognitive deficits are randomised to an individualised pneumoperitoneum pressure strategy (the intervention group) or to a conventional pneumoperitoneum pressure strategy (the control group). The primary outcome is recovery assessed with the Post-operative Quality of Recovery Scale (PQRS) at postoperative day 1. Secondary outcomes include PQRS score in the post anaesthesia care unit and at postoperative day 3, postoperative complications until postoperative day 28, hospital length of stay and process-related outcomes.

(Continued on next page)
**Discussion:** The IPPCollapse-II study will be the first randomised clinical study that assesses the impact of an individualised pneumoperitoneum pressure strategy focused on working with the lowest intra-abdominal pressure during colorectal laparoscopic surgery on relevant patient-centred outcomes. The results of this large study, to be disseminated through conference presentations and publications in international peer-reviewed journals, are of ultimate importance for optimising the care and safety of laparoscopic abdominal surgery. Selection of patient-reported outcomes as the primary outcome of this study facilitates the translation into clinical practice. Access to source data will be made available through anonymised datasets upon request and after agreement of the Steering Committee of the IPPCollapse-II study.

**Trial registration:** ClinicalTrials.gov, NCT02773173. Registered on 16 May 2016. EudraCT, 2016-001693-15. Registered on 8 August 2016.

**Keywords:** Abdominal laparoscopy, Colorectal surgery, Pneumoperitoneum pressure, Outcome, Post-operative Quality of Recovery Scale (PQRS), Postoperative complications, Safety

**Background**

Compared to open surgery, laparoscopic surgery generally results in better outcomes [1, 2]. Compared to open abdominal surgery, a laparoscopic approach during abdominal surgery is associated with less blood loss and fewer needs for blood transfusions [3, 4], faster recovery of bowel function and oral intake resumption [5, 6], fewer analgesic requirements [6, 7] and a shorter length of hospital stay (LOS) [3–8]. Patient-reported outcomes (PROs) are new tools for testing quality of recovery in the postoperative setting, and the Post-operative Quality of Recovery Scale (PQRS) has been successfully tested in previous studies.

A high intraoperative intra-abdominal pressure (IAP) is clearly associated with perioperative morbidity [9–14]. While guidelines for laparoscopic abdominal surgery recommend the lowest possible IAP at which the surgeon has adequate workspace rather than using a predetermined level [15, 16], it remains common practice to use a standard IAP level throughout the surgical procedure, usually between 12 and 15 mmHg and sometimes even higher depending on surgical indication [17]. Interestingly, while the surgical condition depends mainly on the intra-abdominal volume (IAV) and the workspace obtained at a given IAP, the focus during pneumoperitoneum insufflation remains with the applied IAP [18].

Several factors improve the relation between IAP and the obtained surgical workspace, including patient positioning [19], use of neuromuscular blockade [20, 21] and prestretching of the abdominal wall [22]. The previous pivotal and feasibility study, Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery I (IPPCollapse-I), showed that combining all these factors with individualised IAP titration resulted in an acceptable workspace at 8 mmHg IAP in 61 out of 78 patients (78%) [23]. The IPPCollapse-II study presented here tests the hypothesis that this individualised pneumoperitoneum pressure strategy improves recovery of PQRS score when compared to a conventional strategy that uses a fixed pneumoperitoneum pressure approach in patients undergoing scheduled colorectal laparoscopic surgical intervention.

**Methods/design**

**Study reporting**

This report follows the Standard Protocol Items: Recommendations for Interventional Trials and Patient-Reported Outcomes (SPIRIT-PRO) guidelines [24, 25]. Additional file 1 details the IPPCollapse-II SPIRIT checklist.

**Study design**

The IPPCollapse-II study is a multicentre, two-arm, parallel-group, single-blinded randomised clinical study. The enrolment and assessments during the study period are shown in Fig. 1. The study flowchart is shown in Fig. 2.

**Study setting**

The IPPCollapse-II study runs in the operating room and surgical wards of four academic hospitals in Spain (detailed in Additional file 2).

**Study population**

Patients are eligible for participation if they (1) are scheduled for laparoscopic colorectal surgery, (2) are aged > 18 years, (3) have an American Society of Anesthesiologists (ASA) physical status I to III, and (d) have no cognitive deficits. Exclusion criteria are (1) no written informed consent; (2) emergency or unplanned surgery; (3) pregnancy or breastfeeding; (4) immunologic or neuromuscular diseases; (5) advanced stage of cardio-pulmonary, renal or hepatic disease; and (6) allergy to or contraindications for rocuronium or sugammadex.
Randomisation and blinding

Patients are randomised in a 1:1 ratio to an individualised pneumoperitoneum pressure strategy (the intervention group) or a standard pneumoperitoneum pressure strategy (the control group). Local investigators perform randomisation using a web-based automated randomisation system (Biostatistics Unit of the Health Research Institute La Fe, Valencia, Spain). Randomisation is performed with random block sizes and is stratified per centre. While attending anaesthesiologists are aware of the assigned pneumoperitoneum pressure strategy, the attending surgeons as well as the patients remain unaware of the assigned pneumoperitoneum pressure strategy at all times, i.e. before surgery, during surgery and after surgery. The PQRS is a patient-reported outcome (PRO), meaning that the investigator has little room to cause bias. The pneumoperitoneum insufflator screen is covered by a surgical drape. Study team members, who are not blinded to randomisation, perform postoperative PQRS measurements.

Standard pneumoperitoneum pressure strategy

The standard strategy consists of the following elements, to be performed in the same order in all patients in the control group: (1) patients are placed in a position according to the surgeon’s preference within a predefined range of Trendelenburg position (0–30°); (2) patients receive moderate neuromuscular blockade with rocuronium, cisatracurium or atracurium throughout surgery to maintain a train of four (TOF) between 2 and 4; and (3) the IAP is set at 12 mmHg throughout surgery. At any time, surgeons can request an IAP increase if the workspace becomes 'inadequate'; in that case, the IAP is increased in steps of 1 mmHg during 1-min intervals to a maximum of 15 mmHg, but not higher than the level at which the surgical workspace returns to 'adequate'. Surgeons will be warned if the IAP reaches the predefined upper limit.

Neuromuscular blockade pharmacological reversion is achieved with neostigmine (2.5 mg or 30–50 μg·kg⁻¹·h⁻¹), according to usual care.
Individualised pneumoperitoneum pressure strategy

The multifaceted individualised pneumoperitoneum strategy consists of the following elements, which will be performed in the same order in all patients in the intervention group: (1) patient position is modified to increase the anteroposterior intra-abdominal space by correcting lumbar lordosis; (2) patients receive deep neuromuscular blockade throughout surgery to maintain a TOF of 0 and a post-tetanic count (PTC) between 1 and 5; (3) the abdominal wall and muscles are pre-stretched by maintaining an IAP of 15 mmHg for 5 min during the first CO₂ gas insufflation and insertion of trocars (to achieve this, the CO₂ gas insufflator will be initially set at 15 mmHg with a flow rate of 3 L·min⁻¹); and (4) individualised IAP titration is used when the patient is placed in the surgical position (0°–30° Trendelenburg); for this, the flow rate is increased to 30 L·min⁻¹ and the IAP is decreased from 15 to 12 mmHg, and thereafter stepwise to 11, 10, 9 and finally 8 mmHg as long as the attending surgeon keeps an ‘adequate’ workspace. As in the standard pneumoperitoneum pressure group, surgeons can request an IAP increase up to 15 mmHg, which will be performed likewise. Of note, a pressure increment can be requested by the surgeon at all times in both study arms, where it always follows a similar approach; the previous feasibility study showed that an IAP increase was requested only one time in one-fifth of the patients and never twice [23].

Neuromuscular blockade pharmacological reversion at the end of surgery, before tracheal extubation, is achieved with sugammadex 4 mg·kg⁻¹.

For clarity, the elements of the two group strategies are summarised in Table 1.

Standard care

Perioperative management other than the pneumoperitoneum strategy is suggested to follow the Spanish Enhanced Recovery Pathways recommendations (detailed in Additional file 3) [26]. Continuous intraoperative neuromuscular monitoring with acceleromyography (TOF-Watch-SX™, Organon Teknika, Oss, The Netherlands) is used. At the end of surgery, the neuromuscular blockade will be fully reversed to a TOF ratio (TOFr) of at least 0.9 before tracheal extubation. An electronic CO₂ insufflator (Endoflator™, Karl Storz, Tuttingen, Germany) will be used.
for gas insufflation into the abdominal cavity through a parambilically placed laparoscopic trocar/Veress needle.

Patients in both groups will be ventilated in a volume-controlled ventilation mode, using a tidal volume of 8 ml/kg predicted ideal body weight, with a 20% inspiratory pause time, and positive end-expiratory pressure set at 5 or 10 mmHg in patients with a body mass index (BMI) < 30 or ≥ 30 kg·m⁻², respectively. Oxygen inspiratory fraction is 0.8 throughout surgery. Respiratory rate is set at 12–15 breaths per minute to maintain normal end-tidal CO₂ values [27].

**Primary outcome**

The primary outcome is the recovery of the PQRS at postoperative day 1 (POD1) (see the subsequent sections for details).

**Secondary outcomes**

Secondary outcomes include recovery of PQRS at 15 min (T15) and at 40 min (T40) after arrival in the post anaesthesia care unit (PACU) and in the surgical wards during the morning at postoperative day 3 (POD3). Other secondary clinical outcomes include daily postoperative complications until hospital discharge and at postoperative day 28, hospital length of stay (LOS) and secondary process-related outcomes that include the highest IAP level and IAV at which surgery could be performed, hepatic perfusion during pneumoperitoneum and the ventilatory parameters plateau pressure and driving pressure.

Occurrences of diaphragm and abdominal wall contractions or spontaneous breathing efforts and coughing during surgery are collected and compared between the two study groups.

### Table 1 Intervention sequence

| Standard pneumoperitoneum pressure strategy (SPP group) | Individualised pneumoperitoneum pressure strategy (IPP group) |
|--------------------------------------------------------|------------------------------------------------------------|
| 1. Trendelenburg (0–30°) placement                     | 1. Trendelenburg (0–30°) + ‘modified lithotomy position’, with flexed hips (between 45 and 90°) and legs raised in padded supports to increase anteroposterior intra-abdominal space |
| 2. Moderate neuromuscular blockade throughout surgery (TOF between 2 and 4) | 2. Deep neuromuscular blockade throughout surgery (TOF of 0 and a PTC between 1 and 5) |
| 3. No prestretching of abdominal wall muscles          | 3. Prestretching of abdominal wall muscles by maintaining an IAP of 15 mmHg for 5 min during the first CO₂ gas insufflation and insertion of trocars (flow rate at 3 L·min⁻¹) |
| 4. IAP is set at 12 mmHg throughout surgery            | 4. IAP down-titration (flow rate at 30 L·min⁻¹) from 15 to 12 mmHg, and thereafter step wise to 11, 10, 9 and finally 8 mmHg as long as ‘adequate’ workspace is preserved (by surgeon’s judgement) |
| 5. Surgeons can request an IAP increase if workspace becomes ‘inadequate’. IAP is increased in steps of 1 mmHg during 1-min intervals to a maximum of 15 mmHg. Surgeons are warned when upper limit is reached | 5. Surgeons can request an IAP increase if workspace becomes ‘inadequate’; IAP is increased in steps of 1 mmHg during 1-min intervals to a maximum of 15 mmHg. Surgeons are warned when upper limit is reached |

TOF train of four, IAP intra-abdominal pressure, PTC post-tetanic count

**Substudies**

The IPPCollapse-II study has three substudies (see the detailed description in Additional file 4):

1. Levels of biomarkers (neutrophil-lymphocyte ratio, C-reactive protein, interleukin-6 and procalcitonin) are measured in peripheral venous blood samples obtained before surgery and at POD1 and POD3 and compared between the two study groups. For this substudy, blood samples are obtained in all participating centres.
2. Untargeted metabolomic analysis is performed on peripheral venous blood samples and peritoneal tissue, both obtained after initial insufflation of pneumoperitoneum and at the end of the procedure. This substudy includes the first 10 patients in the Hospital Universitari i Politècnic La Fe, Valencia, Spain.
3. Plasma disappearance rate of indocyanine green (PDRICG) after intravenous ICG injection is measured to evaluate hepatic perfusion during pneumoperitoneum as a marker of liver function [28]. This substudy runs only at the University Hospital Gregorio Marañon, Madrid, Spain.

**Post-operative Quality of Recovery Scale**

The PQRS is a validated multidimensional PRO tool [29–31] designed to assess patients’ recovery to baseline status in the postoperative period (www.postopqrs.com). In every patient a baseline measurement of PQRS is performed prior to surgery. After surgery, the measurement of the PQRS is repeated at 15 min (T15) and at 40 min (T40) after arrival in the PACU, as well as in the ward on the morning of POD1 and POD3. The PQRS is a verbal survey tool that depicts recovery in the following five domains: physiologic, nociceptive, emotive, functional,
cognitive, and also collects overall patient perspective. Each of these domains is assessed with multiple items on an ordinal scale and compared with baseline to evaluate recovery (see Table 2 for details). Recovery is a dichotomised outcome defined by a return to at least baseline values or better at each of the postoperative measurement time points. Overall recovery requires recovery in all domains being assessed, and failure in any domain results in failure of overall recovery.

Definitions
The IAP will be recorded as read from the gas insufflator device. In the intervention group the ‘individualised IAP’ is defined as the highest IAP needed to obtain and maintain an adequate workspace until completion of surgery. The IAV is calculated by linear interpolation from the patient’s IAP/IAV curve obtained during initial pneumoperitoneum insufflation matching to the IAP at which surgery is performed.

‘Adequate’ workspace is defined as the intra-abdominal workspace sufficient to perform the surgical procedure with no need for corrective manoeuvres (i.e. IAP increase) as judged by the attending surgeon, who remains blinded for the actual IAP. Consequently, ‘inadequate’ workspace is defined as an intra-abdominal workspace insufficient to perform the surgical procedure with the need for corrective manoeuvres (i.e. IAP increase).

Definitions of the various postoperative complications recorded are in accordance with the current European standards for perioperative outcomes (Table 3) [32]. Severity of postoperative complications is evaluated using Clavien-Dindo grading (Table 4) [33].

Table 2: Post-operative Quality of Recovery Scale (PQRS)

| Domain            | Variable                        | Score | Baseline | T15  | T40  | POD1 | POD3 |
|-------------------|---------------------------------|-------|----------|------|------|------|------|
| Physiologic       | Blood pressure                  | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Heart rate                      | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Temperature                     | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Respiration                     | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | SpO2                            | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Airway                          | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Agitation                       | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Consciousness                   | 1–3   | +        | +    | +    | +    | +    |
| Physiologic       | Activity on command             | 1–3   | +        | +    | +    | +    | +    |
| Nociceptive       | Pain                            | 1–5 Likert | +    | +    | +    | +    |
| Nociceptive       | PONV                            | 1–5 Likert | +    | +    | +    | +    |
| Emotional         | Sadness/depression              | 1–5 Likert | +    | +    | +    | +    |
| Emotional         | Anxiety/nervousness             | 1–5 Likert | +    | +    | +    | +    |
| Functional        | Stand                           | 1–3   | +        | –    | –    | +    | +    |
| Functional        | Walk                            | 1–3   | +        | –    | –    | +    | +    |
| Functional        | Eat/drink                       | 1–3   | +        | –    | –    | +    | +    |
| Functional        | Get dressed                     | 1–3   | +        | –    | –    | +    | +    |
| Cognitive         | Name, city and DOB              | TF 0  | +        | –    | –    | +    | +    |
| Cognitive         | Numbers forward                 | TF 2  | +        | –    | –    | +    | +    |
| Cognitive         | Numbers backwards               | TF 1  | +        | –    | –    | +    | +    |
| Cognitive         | Word task: list                 | TF 3  | +        | –    | –    | +    | +    |
| Cognitive         | Executive memory                | TF 3  | +        | –    | –    | +    | +    |
| Overall patient perspective | Ability to work     | 1–5   | –        | –    | –    | –    | –    |
| Overall patient perspective | Ability to perform ADLs      | 1–5   | –        | –    | –    | –    | –    |
| Overall patient perspective | Clarity of thought         | 1–5   | –        | –    | –    | –    | –    |
| Overall patient perspective | Satisfaction anaesthesia care  | 1–5   | –        | –    | –    | –    | –    |

Online scale to assess multiple domains of postoperative recovery over time. Timeline: T15–15 min in PACU, T40–40 min in PACU Scoring: Physiologic 1–3; Nociceptive/emotional 1–5; Likert rating scale using a faces pictorial display; Functional: Scored as 3 easily, 2 with difficulty, 1 not at all; Cognitive: Performance variability tolerance factor (TF) is applied. Participants not included in subsequent analysis if baseline scores are equal to or less than the TF PACU post-anæthesia care unit, POD1 postoperative day 1, POD3 postoperative day 3, SpO2 blood oxygen saturation, PONV postoperative nausea and vomiting, DOB date of birth, ADL activity of daily living.
from Pressure plateau (Pplat) [34]. Perioperative safety issues are recorded during the surgery and are related to involuntary patient movements, and defined as dia-

phragm or abdominal wall contractions or spontaneous breathing efforts or coughing during anaesthesia.

Hospital LOS is defined as hospital discharge date minus hospital admission date.

Data to be collected
Before anaesthesia demographic data will be collected including age (years), gender, body height (centimetres) and body weight (kilograms), BMI (kilograms per metre squared), ASA physical status score, comorbidities, number of previous abdominal surgeries and number of previous laparoscopic surgeries and PQRS score.

During anaesthesia the following data will be obtained: levels of IAPs at which surgery is performed (mmHg) in both groups; proportion of patients who needed a pressure increment to achieve acceptable surgical workspace; IAV at start of pneumoperitoneum (litres); coughing and spontaneous movements (yes/no); type of surgery and oncologic status; duration of surgery (minutes); duration of anaesthesia (minutes); proportion of patients who needed conversion from laparoscopic to open surgery and the reason for it (only if applicable); ventilation data including PEEP, plateau pressure and respiratory driving pressure (ΔPrs) (all in centimetres of H2O pressure) before pneumoperitoneum generation and during initial IAP titration until a stable level of IAP is reached in both groups; type and dose of neuromuscular blocking agent (milligrams); type and dose of neuromuscular blocking reversal agent (milligrams); total opioid requirement during the first 24 h if used (milligrams); and PDRICG in the stable pneumoperitoneum phase.

Directly after anaesthesia, in the PACU the following will be obtained: PQRS score at 15 and 40 min after PACU admission and on POD1 and POD3; PQRS score in the morning and peripheral venous blood samples for determination levels of biomarkers.

On all postoperative days until hospital discharge and at day 28 the occurrence of postoperative complications and location will be noted.

Analysis plan
The statistical analysis plan (SAP) is specified before enrolment of the first patient. In the absence of studies assessing differences in recovery, based on intraoperative IAP management during laparoscopic colorectal surgery, we performed the sample size calculation assuming an odds ratio of 2.65 (equivalent to a difference of 0.5 unit in the logit scale) between groups in the recovery of physiologic PQRS score. It was estimated that a sample size of 170 patients is required to achieve 80% power at a significance level of alpha = 0.05. All reasons for dropouts, expected to be as low as 10%, will be collected and reported. Conversion to open surgery was the main reason for dropouts in the previous study. We will recruit a total of 190 patients to compensate for potential losses.

All analyses will be performed with R software (R Foundation for Statistical Computing, Vienna, Austria). Data will be expressed as the mean (standard deviation, SD) or median (interquartile range, IQR) for continuous variables depending on their distribution (normality will be checked with the Shapiro–Wilks test) and by counts and proportions for categorical variables. The 95% confidence intervals will be calculated for each of the estimated percentiles. The statistical significance level will be set at $P < 0.05$.

The analysis of the primary endpoint follows the intention-to-treat principle. The difference between the recovery PQRS score between groups, the primary

Table 3 Classification of postoperative complications

| 1. Acute kidney damage |
| 2. Acute respiratory distress syndrome (ARDS) |
| 3. Suture dehiscence |
| 4. Arrhythmia |
| 5. Cardiac arrest |
| 6. Cardiogenic pulmonary edema |
| 7. Deep vein thrombosis |
| 8. Postoperative delirium |
| 9. Gastrointestinal bleeding |
| 10. Infection |
| 11. Bacteraemia |
| 12. Myocardial infarction |
| 13. Myocardial injury after non-cardiac surgery |
| 14. Pneumonia |
| 15. Paralytic ileus |
| 16. Postoperative haemorrhage |
| 17. Pulmonary embolism |
| 18. Cerebrovascular accident |
| 19. Infection of surgical wound (superficial) |
| 20. Infection of surgical wound (deep) |
| 21. Infection of surgical (organ) wound |
| 22. Urinary tract infection |

Postoperative pulmonary complications:

1. Respiratory infection
2. Respiratory failure
3. Pleural effusion
4. Atelectasis
5. Pneumothorax
6. Bronchospasam
7. Pneumonia due to aspiration

from Pressure plateau (Pplat) [34]. Perioperative safety issues are recorded during the surgery and are related to involuntary patient movements, and defined as dia-

phragm or abdominal wall contractions or spontaneous breathing efforts or coughing during anaesthesia.

Hospital LOS is defined as hospital discharge date minus hospital admission date.

Data to be collected
Before anaesthesia demographic data will be collected including age (years), gender, body height (centimetres) and body weight (kilograms), BMI (kilograms per metre squared), ASA physical status score, comorbidities, number of previous abdominal surgeries and number of previous laparoscopic surgeries and PQRS score.

During anaesthesia the following data will be obtained: levels of IAPs at which surgery is performed (mmHg) in both groups; proportion of patients who needed a pressure increment to achieve acceptable surgical workspace; IAV at start of pneumoperitoneum (litres); coughing and spontaneous movements (yes/no); type of surgery and oncologic status; duration of surgery (minutes); duration of anaesthesia (minutes); proportion of patients who needed conversion from laparoscopic to open surgery and the reason for it (only if applicable); ventilation data including PEEP, plateau pressure and respiratory driving pressure (ΔPrs) (all in centimetres of H2O pressure) before pneumoperitoneum generation and during initial IAP titration until a stable level of IAP is reached in both groups; type and dose of neuromuscular blocking agent (milligrams); type and dose of neuromuscular blocking reversal agent (milligrams); total opioid requirement during the first 24 h if used (milligrams); and PDRICG in the stable pneumoperitoneum phase.

Directly after anaesthesia, in the PACU the following will be obtained: PQRS score at 15 and 40 min after PACU admission and on POD1 and POD3; PQRS score in the morning and peripheral venous blood samples for determination levels of biomarkers.

On all postoperative days until hospital discharge and at day 28 the occurrence of postoperative complications and location will be noted.

Analysis plan
The statistical analysis plan (SAP) is specified before enrolment of the first patient. In the absence of studies assessing differences in recovery, based on intraoperative IAP management during laparoscopic colorectal surgery, we performed the sample size calculation assuming an odds ratio of 2.65 (equivalent to a difference of 0.5 unit in the logit scale) between groups in the recovery of physiologic PQRS score. It was estimated that a sample size of 170 patients is required to achieve 80% power at a significance level of alpha = 0.05. All reasons for dropouts, expected to be as low as 10%, will be collected and reported. Conversion to open surgery was the main reason for dropouts in the previous study. We will recruit a total of 190 patients to compensate for potential losses.

All analyses will be performed with R software (R Foundation for Statistical Computing, Vienna, Austria). Data will be expressed as the mean (standard deviation, SD) or median (interquartile range, IQR) for continuous variables depending on their distribution (normality will be checked with the Shapiro–Wilks test) and by counts and proportions for categorical variables. The 95% confidence intervals will be calculated for each of the estimated percentiles. The statistical significance level will be set at $P < 0.05$.

The analysis of the primary endpoint follows the intention-to-treat principle. The difference between the recovery PQRS score between groups, the primary
outcome on POD1, will be assessed by mixed ordinal logistic regression introducing the patient as random factor, and age, weight, BMI and sex as covariables. The differences in Clavien-Dindo grading of postoperative complications will be assessed by ordinal regression.

For IAV calculation the relationship between IAP and CO₂ insufflated volume will be determined for each patient during initial pneumoperitoneum insufflation. The relationship between IAP and IAV was analysed by linear interpolation from the individual IAP/IAV curves. The IAP before CO₂ gas insufflation (IAP at volume zero) will be estimated by fitting multiadaptive linear regression splines to the IAV and IAP relationship. If a variable has a frequency of missing data > 5%, data will be imputed by the multiple imputation method.

As there is no ethically unacceptable risk related to the primary outcome analysed, there will be no planned interim analysis.

### Adverse events

All adverse events (AEs) or serious adverse events (SAEs), related to the study medication or not, will be followed up by the investigators and documented in the electronic case report form (eCRF) up to 28 days after the end of the intervention period. All SAEs will be notified to the Steering Committee and promoter of the study as soon as the researcher has knowledge of the SAEs, but not more than 24 h after the researcher becomes aware of the event.

### Auditing

Sites may be subject to audits, independent ethics committee (IEC)/Institutional Review Board (IRB) review and regulatory inspection(s). Local investigators will provide direct access to the source data documents (see Additional file 4 for full details).

### Ethics and dissemination

The study will be carried out according to a protocol reviewed and approved at a national level by the IRB of Hospital Universitari i Politècnic La Fe, Valencia, Spain, and Agencia Española del Medicamento y Productos Sanitarios (AEMPS). The study has been registered at ClinicalTrials.gov (identifier NCT02773173, May 16,

---

**Table 4** Severity grade by Clavien-Dindo definition

| Grade | Definition                                                                 |
|-------|---------------------------------------------------------------------------|
| I     | Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic or radiological interventions |
|       | Allowed therapeutic regimens are drugs as antiemetic, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside |
| II    | Requiring pharmacological treatment with drugs other than such allowed for Grade I complications |
|       | Blood transfusions and total parenteral nutrition are also included |
| III   | Requiring surgical, endoscopic or radiological intervention |
|       | - IIIa Intervention not under general anaesthesia |
|       | - IIIb Intervention under general anaesthesia |
| IV    | Life-threatening complication (including CNS complications)* requiring IC/ICU management |
|       | - IVa Single organ dysfunction (including dialysis) |
|       | - IVb Multiorgan dysfunction |
| V     | Death of a patient |

*Brain haemorrhage, ischaemic stroke, subarachnoidal bleeding, but excluding transient ischaemic attacks (TIAs) |

IC intermediate care, ICU intensive care unit, CNS central nervous system
2016) and EudraCT (2016-001693-15), and is conducted in accordance with the Declaration of Helsinki on ethical principles for medical research in human subjects, adopted by the General Assembly of the World Medical Association (1996). Data management, monitoring and reporting of the study are performed in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines (CPMP/ICH/135/95) and the regulatory requirements for participating institutions by the Spanish Clinical Research Network (SCReN). Investigators collect a written informed consent form in compliance with the GCP recommendations to the patient or his/her legal representative if the patient’s clinical conditions do not allow him/her to review and approve it. Investigators provide a copy of the signed informed consent form to each subject and keep a copy in the subject’s study file. This study protocol is reported following the Standard Protocol Items: Recommendations for Interventional Trials and Patient-Reported Outcomes (SPIRIT-PRO) guidelines [24, 25].

The results of the study will be communicated through the portal of the European Medicines Agency and will be sent for publication in a peer-reviewed medical journal. Authorship will be based on International Committee of Medical Journal Editors (ICMJE) criteria. No professional writer will be involved. After publication of the primary results, upon request, the pooled dataset will be available for all members of the IPPCollapse-II study group for secondary analysis, after judgement and approval of the scientific quality and validity of the proposed analysis by the Steering Committee. Access to source data will be made available through national or international anonymised datasets upon request and after agreement of the IPPCollapse-II Steering Committee.

Discussion
This study is the first randomised clinical study that tests the hypothesis that an individualised pneumoperitoneum pressure strategy focusing on using the lowest possible IAP, compared to a conventional pneumoperitoneum pressure strategy, improves recovery after laparoscopic colorectal surgery. This study uses the PQRS as well as the occurrence of postoperative complications until postoperative day 28 and also hospital LOS. Furthermore, we assess process-related outcomes like IAP and IAV during pneumoperitoneum and associated ventilator parameters. A strong multidisciplinary commitment between members of the perioperative team, consisting of surgeons and anaesthesiologists, makes this complex study feasible.

The IPPCollapse-II study has several strengths. Its prospective design will allow high accuracy of data to be collected, and its sample size allows us to draw valid conclusions. Selection of PROs as the primary outcome of this study facilitates the translation into clinical practice, since these outcomes are readily and easily perceivable by both patients and healthcare providers. To the best of our knowledge, this is the first multicentre randomised clinical study evaluating the clinical effect of a tailored IAP management. The surgeon will remain blinded for the IAP, allowing us to titrate the IAP to the lowest possible level, i.e. the level at which surgeons have adequate workspace. Furthermore, we aim to describe the relationship between the IAP and actual IAV at which surgery is performed. This could lead, on the one hand, to gathering evidence towards establishing a volume threshold (e.g. the actual workspace) for colorectal laparoscopic surgery to replace the standard pressure threshold, and on the other, to describing the abdominal pressure-volume relationship in a first attempt to achieve something similar to our understanding of lung dynamics during ventilation. Additionally, we directly link the respiratory system and abdomen by assessing the IAP and respiratory driving pressure relationship. This could bring us a step further in achieving protective ventilation in the operating room.

The study proposed here differs from previous studies on this topic. Most studies so far have evaluated the individual components of the multifaceted strategy and are largely focused on surgical conditions and not patient-centred outcomes. Also, they generally find minor gains from abdominal prestretching or patient positioning optimisation and offer inconclusive results or marginally positive effects for the level of neuromuscular blockade [35–45]. Two studies find IAP titration useful in decreasing conventional IAP management, but they do not focus on clinical outcomes [46, 47].

To our knowledge, only one study so far focused on quality of recovery, using the Quality of Recovery 40 (QoR-40), a 40-item questionnaire on quality of recovery from anaesthesia [36]. This study, comparing surgery at low IAP (6 mmHg) versus standard IAP (12 mmHg) during laparoscopic donor nephrectomy under deep neuromuscular blockade, found no differences in QoR-40 score. Of note, in this study surgeons were not blinded for the IAP and in 25% of patients surgery had to be converted to the standard pressure, probably due to the surgeon’s learning curve. We recently performed the IPPCollapse-I study, in which we evaluated the feasibility of the intervention being
tested in the present study [23]. The intervention was found to be safe and highly feasible and resulted in an acceptable workspace at low IAP in most patients. We did not look at patient outcomes in the preceding study.

The PQRS has been successfully tested in previous studies to evaluate differences in recovery [48–51]. We acknowledge that finding differences in PROs by PQRS modifying a single strategy in a high quality environment could be difficult [52–54]. In order to evaluate minor differences in recovery, mainly in laboratory data, we perform three substudies. Levels of biomarkers (neutrophil-lymphocyte ratio, C-reactive protein, interleukin-6 and procalcitonin) in the postoperative recovery period are linked to immunosuppression and postoperative complications [55, 56]. Untargeted metabolomic intraoperative analyses of blood samples and peritoneum biopsies allow us to depict differences between groups in the intraoperative setting and generate a hypothesis for new studies. PDRICG has been used successfully to evaluate hepatic perfusion in critically ill patients with intra-abdominal hypertension [28] and could reveal differences in hepatic perfusion during pneumoperitoneum in this study.

This study has limitations. We exclude ASA IV patients, who could benefit more from working with low IAP. Since we test a multifaceted strategy, it will remain uncertain which part of the strategy will have the largest impact. In fact, it could very well be that not all parts have the same magnitude of effect, and it is even possible that some parts have negligible effects. Of note, reversal of neuromuscular blockade with sugammadex instead of neostigmine could improve PQRS recovery at T40 although not at POD1 or POD3. Surgeons, blinded for the actual IAP, will evaluate surgical conditions in a practical dichotomous manner as adequate or not, depending on whether any corrective action is needed. This way of measurement might make comparisons with other studies difficult, such as those using the Leiden-Surgical Rating Scale. The anaesthesiologists collecting the PQRS evaluations are not blinded for the assigned strategy, as they were present during the surgical procedure. However, the risk of bias will be very low, as the PQRS is a ‘patient-reported’ outcome, and the patients remain blinded at all times, including the time at which the PQRS score is collected. We calculated the sample size of our study on PQRS differences; thus, our sample could be underpowered for some secondary outcome that can potentially require a larger sample. In conclusion, the IPPCollapse-II study is designed to test if an individualised pneumoperitoneum pressure and optimised management versus conventional care will affect the outcome of patients undergoing colorectal laparoscopic surgery using relevant patient-centred outcomes.

3.1. Trial status
The Protocol Version is Version 1.0; June 7, 2016. A competent IRB, as detailed in the text, approved this version of the protocol. Recruitment began on February 1st, 2017. The expected date for recruitment completion is October–November 2018.

Additional files

Additional file 1: Reporting SPIRIT checklist for protocol IPPCollapse-II. (DOCX 27 kb)
Additional file 2: Collaborating centres in the IPPCollapse-II study and expected number of patients recruited. (DOCX 12 kb)
Additional file 3: Enhanced Recovery Pathways Spanish guidelines summary. RICA (Intensive recovery in abdominal surgery) (DOCX 126 kb)
Additional file 4: Protocol for substudies document. (DOCX 24 kb)

Abbreviations
ASA: American Society of Anesthesiologists; BMI: Body mass index; eCRF: Electronic case report form; GCP: Good Clinical Practice; IAP: Intra-abdominal pressure; IAV: Intra-abdominal volume; IPPCollapse: Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery versus Standard Therapy; IRB: Institutional Review Board; LOS: Length of (hospital) stay; PACU: Post anaesthesia care unit; PDRICG: Plasma disappearance rate of indocyanine green; PEEP: Positive end-expiratory pressure; POD: Postoperative day; PQRS: Post-operative Quality of Recovery Scale; PRO: Patient-reported outcome; PTc: Post-tetanic count; SCReN: Spanish Clinical Research Network; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; TOF: Train of four; UPLC: Ultra performance liquid chromatography; ΔPrs: Respiratory system driving pressure.

Acknowledgements
Complete list of the IPPCollapse-II investigators
Oscar Díaz-Cambronero (oscardiazcambronero@gmail.com)
Blas Flor-Lorente (bflorlor@hotmail.com)
Guido Mazzinari (gmazzinari@gmail.com)
María Vilà-Montañés (mvilamontanes@yahoo.es)
Nuria García-Gregorio (nuriagcia6@gmail.com)
Maria Jose Alberola-Estelles (majoni2000@yahoo.es)
Begoña Ayas-Montero (begoya@hotmail.com)
Salome Matoses-Jaén (smatosesj@gmail.com)
Sandra Verdeguer (sandraverdeguer@hotmail.com)
Anabel Marqués Mari (amarquesmari@gmail.com)
Jose Miguel Alonso Iñigo (jmalonso@me.com)
Josep Balaguer Domenech (jbalaguer.doc@gmail.com)
Marisol Echeverri Velez (maechevelez@hotmail.com)
David Cuesta-Frau (dcuesta@disca.upv.es)
Maria Pilar Argente-Navarro (argente_mamavi@gva.es)
Salvador Pous (salvadorpous@hotmail.com)
Cristina Ballester (cri7balle@yahoo.es)
Matteo Frasson (dr.frasson.matteo@gmail.com)
Alvaro Garcia-Granero (alvaroggr@gmail.com)
Carlos Cerdán-Santacruz (carloscerdansantacruz@hotmail.com)
Eduardo García-Granero (eggranero@telefonica.net)
Luis Sánchez-Guillén (lguillen@clusa.com)
Daniel Robles-Hernández (drobher@gmail.com)
David Boquera-Albert (david.boquera@gmail.com)
David Casado-Rodrigo (dcasador@hotmail.com)
Rebeca Cosa-Rodríguez (rebecacosar@hotmail.com)
informed consent form to each subject and keep a copy in the subject's clinical file. Investigators provide a copy of the signed consent form in compliance with the GCP recommendations to the patient and the regulatory requirements for participating institutions by the Spanish Harmonisation Good Clinical Practice guidelines (ICH) (CPMP/ICH/135/95) (1996). Data management, monitoring and reporting of the study are conducted in accordance with the Declaration of Helsinki on ethical principles for medical research in human subjects, adopted by the General Assembly of the World Medical Association. The study has been approved at a national level by the Institutional Review Board (IRB) of the Hospital Universitari i Politècnic La Fe, Valencia, Spain. Ethics approval and consent to participate

This is an investigator-initiated study in which the sponsors and funders have no roles in the study's design, analysis of data and reporting. This work was supported by Merck Sharp & Dohme (grant number #53607; $105,672). The Health Research Institute of the Hospital Universitari i Politècnic La Fe, Valencia, Spain, is the sponsor of this study. The Ministry of Economy and Competitiveness, the Carlos III Health Institute and the National Investigation/Development/Innovation Plan fund the platform for the Clinical Research and Clinical Trials Units of the Health Research Institute of the Hospital Universitari i Politècnic La Fe (PT17/0017/0035). The Spanish Clinical Research Network provides clinical trial data monitoring and oversees pharmacovigilance.

Availability of data and materials

Access to source data will be made available through anonymised datasets upon request and after agreement of the Steering Committee of the IPPCollapse-II study.

Authors' contributions

ODC designed the study, is on the Steering Committee and drafted and revised the manuscript; GM designed the study, is on the Steering Committee and drafted and revised the manuscript; CLE designed the study, is on the Steering Committee and drafted and revised the manuscript; BFL designed the study, is on the Steering Committee and drafted and revised the manuscript; MVM designed the study and drafted and revised the manuscript; DRH designed the study and drafted and revised the manuscript; LEOA designed the study and drafted and revised the manuscript; AMdP designed the study and drafted and revised the manuscript; MVM designed the study and drafted and revised the manuscript; MPN designed the study and drafted and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study will be carried out according to a protocol reviewed and approved at a national level by the Institutional Review Board (IRB) of Hospital Universitari i Politècnic La Fe, Valencia, Spain, and Agencia Española del Medicamento y Productos Sanitarios (AEMPS). The study has been registered at ClinicalTrials.gov (identifier NCT02773173, May 16, 2016) and EudraCT (2016-001693-15), and is conducted in accordance with the Declaration of Helsinki on ethical principles for medical research in human subjects, adopted by the General Assembly of the World Medical Association (1996). Data management, monitoring and reporting of the study are performed in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines (ICH) (CPMP/ICH/135/95) and the regulatory requirements for participating institutions by the Spanish Clinical Research Network (SCReN). Investigators collect a written informed consent form in compliance with the GCP recommendations to the patient or his/her legal representative if the patient's clinical conditions do not allow him/her to review and approve it. Investigators provide a copy of the signed informed consent form to each subject and keep a copy in the subject's study file.

Consent for publication

Not applicable.

Competing interests

Oscar Diaz-Cambronero received a grant from the Merck Investigator Studies Program Review Committee (MISP-RC), Merck Sharp & Dohme, protocol code #53607 with $109,672 and speakers' fees and honoraria from Merck Sharp & Dohme for lectures ($8,000); Carlos L. Errando received speakers' fees and honoraria for lectures from Merck Sharp & Dohme ($1,000); Blandin Flor-Lorente received speakers' fees and honoraria from Merck Sharp & Dohme for lectures ($3,000); Maria Pilar Argente Navarro received speakers' fees and honoraria for lectures from Merck Sharp & Dohme ($1,000); Guido Mazzinari, Nuria García Gregorio, María Vila Montañés, Daniel Robles Hernandez, Luis Enrique Olmedilla-Arnal, Angel Martín de Pablos, Anabel Marques Mari and Marcus J. Schultz declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of Anaesthesiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. 2. Perioperative Medicine Research Group, Instituto de Investigación Sanitaria La Fe (IIS laFe), Avinguda de Fernando Abril Martorell 106, 46026 Valencia, Spain. 3. SCReN-HS La Fe, PT17/0017/0035; Spanish Clinical Research Network (SCReN), Valencia, Spain. 4. Department of Anaesthesiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. 5. Department of Anaesthesiology, Consorcio Hospital General Universitario de Valencia, Valencia, Spain. 6. Department of Anaesthesiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. 7. Department of Anaesthesiology, Hospital General Universitario de Castellón, Castellón, Spain. 8. Department of Anaesthesiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 9. Department of Anaesthesiology, Hospital Universitario Virgen Macarena, Sevilla, Spain.

Received: 30 July 2018 Accepted: 27 February 2019 Published online: 03 April 2019

References

1. Trastulli S, Ciocchi R, Listorti C, et al. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Color Dts. 2012;14: 277–96.
2. Van Vught JLA, Reisinger KW, Derikx JPM, et al. Improving the outcomes in oncological colorectal surgery. World J Gastroenterol. 2014;20:12445–57.
3. Lacy AM, García-Valdecasas JC, Delgado S, et al. Laparoscopic-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2005;365:1718–26.
4. Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent D, Wieand H, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.
5. Guillou P, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–26.
6. Veldkamp R, Kühry E, Hop W, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6:477–84.
7. Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. 2010;11:637–45.
8. Braga M, Frasson M, Vignali A, et al. Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis. Dis Colon Rectum. 2007;50:464–71.
9. Maddison L, Karajanin J, Tenhunen J, et al. Moderate intra-abdominal hypertension is associated with an increased lactate-pyruvate ratio in the rectus abdominis muscle tissue: a pilot study during laparoscopic surgery. Ann Intensive Care. 2012;2(Suppl 1):S14.
10. Matsuaki S, Jordon K, Maleysson E, et al. Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal environment. Hum Reprod. 2012;27(6):1613–23.
11. Sammour T, Mital A, Lovelad BPT, et al. Systematic review of oxidative stress associated with pneumoperitoneum. Br J Surg. 2009;96:836–50.
12. Brokelman WJA, Lensvelt M, Rinkes IHMB, et al. Peritoneal changes due to laparoscopic surgery. Surg Endosc. 2011;25:1–9.
13. Schwarte LA, Scheeren TWL, Lorenz C, et al. Moderate increase in intraabdominal pressure attenuates gastric mucosal oxygen saturation in patients undergoing laparoscopy. Anesthesiology. 2004;100:1081–7.
14. Barczyński M, Herman RW. A prospective randomized trial on comparison of low-pressure (LP) and standard-pressure (SP) pneumoperitoneum for laparoscopic cholecystectomy. Surg Endosc. 2003;17:533–8.
15. Neudecker J, Sauerland S, Neugebauer E, et al. The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery. Surg Endosc. 2002;16:121–41.
16. Hatipoglu S, Akbulut S, Hatipoglu F, et al. Effect of laparoscopic abdominal surgery on splanchic circulation: historical developments. World J Gastroenterol. 2014;20:18165–76.
17. Jones O, Lindsey I, Cunningham C. Laparoscopic colorectal surgery. Br Med J. 2014;349:w197–203.
18. Vlot J, Wiljen R, Stolker RJ, et al. Optimizing working space in porcine laparoscopy: CT measurement of the effects of intra-abdominal pressure. Surg Endosc. 2013;27:1668–73.
19. Muller JP, Dillemans B, Van Cauwenberge S. Impact of the patient’s body position on the intra-abdominal workspace during laparoscopic surgery. Surg Endosc. 2010;24:398–402.
20. Madsen MV, Staehr-Rye AK, Gätke MR, et al. Neuromuscular blockade for optimising surgical conditions during abdominal and gynaecological surgery: a systematic review. Acta Anaesthesiol Scand. 2015;59:1–16.
21. Bruintjes MH, Van Helden EV, Baat AE, et al. Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis. Br J Anaesth. 2017;118:834–42.
22. Vlot J, Wiljen R, Stolker RJ, et al. Optimizing working space in laparoscopy: CT measurement of the effect of pre-stretching of the abdominal wall in a porcine model. Surg Endosc. 2014;28:841–6.
23. Diaz-Cambronero O, Flor Lorente B, Mazzini G, et al. A multifaceted individualized pneumoperitoneum strategy for laparoscopic colorectal surgery: a multicenter observational feasibility study. Surg Endosc. 2019;33(1):252–60.
24. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Br Med J. 2013;346:1–42.
25. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319:483–94.
26. Ministério de Sanidad SS, Instituto Aragonés de Ciencias de la Salud. ViaClínica-RICA. 2018. Report No. (NIPO) 680-15-085-5. http://portal.gva.sald.es/contenido/frames/documentos/oppe/2015-07/ViaClinica-RICA.Pdf. Accessed 15 Mar 2018.
27. Serpa Neto A, Hemees SNT, Barbas CSV, et al. Protective versus conventional ventilation for surgery: a systematic review and patient data meta-analysis. Anesthesiology. 2015;123:66–78.
28. Malbrain MLNG, Vlaene D, Kortgen A, et al. Relationship between intra-abdominal pressure and indocyanine green plasma disappearance rate: hepatic perfusion may be impaired in critically ill patients with intra-abdominal hypertension. Ann Intensive Care. 2012;2:2015Suppl 11519.
29. Rosse CF, Newman S, Chung F, et al. Development and feasibility of a scale to assess postoperative recovery. Anesthesiology. 2010;113:892–905.
30. Bowyer A, Jakobsson J, Ljungqvist O, et al. A review of the scope and optimising surgical conditions during abdominal hypertension. Anesthesiology. 2014;120:51.
31. Calvert MJ, Cottrell AE, MacMinn C, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the EASA-EICM joint taskforce on perioperative outcome measure. Eur J Anaesthesiol. 2015;32:288–105.
32. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
33. Royse CF, Saager L, Whitlock R, et al. Association between driving pressure and development of postoperative pulmonary complications in patients undergoing mechanical ventilation for general anaesthesia: a meta-analysis of individual patient data. Lancet Respir Med. 2016;4:272–80.
54. Pérez Herrero MA, López Álvarez S, Fadrique Fuentes A, et al. Calidad de la recuperación posquirúrgica tras cirugía de mama. Anestesia general combinada con bloqueo paravertebral versus bloqueo del espacio serrato-intercostal. Rev Esp Anestesiol Reanim. 2016;63:564–71.

55. Ni Eochagain A, Burns D, Riedel B, Sessler DI, Buggy DJ. Effect of anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and time of commencement of intended oncologic therapy: a follow-up analysis of a prospective randomised trial. Anaesthesia. 2018;73:603–11.

56. García-Granero A, Frasson M, Flor-Lorente B, et al. Procalcitonin and C-reactive protein as early predictors of anastomotic leak in colorectal surgery: a prospective observational study. Dis Colon Rectum. 2013;56:473–83.